2.93
price up icon4.64%   +0.13
 
loading
Elutia Inc stock is currently priced at $2.93, with a 24-hour trading volume of 11,821. It has seen a +4.64% increased in the last 24 hours and a -7.28% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.83 pivot point. If it approaches the $2.96 resistance level, significant changes may occur.
Previous Close:
$2.80
Open:
$2.9
24h Volume:
11,821
Market Cap:
$71.35M
Revenue:
$35.35M
Net Income/Loss:
$-37.66M
P/E Ratio:
-1.3022
EPS:
-2.25
Net Cash Flow:
$-22.11M
1W Performance:
+5.40%
1M Performance:
-7.28%
6M Performance:
+113.87%
1Y Performance:
+0.00%
1D Range:
Value
$2.85
$2.99
52W Range:
Value
$1.1001
$4.1893

Elutia Inc Stock (ELUT) Company Profile

Name
Name
Elutia Inc
Name
Phone
240 247 1170
Name
Address
12510 Prosperity Drive, Suite 370, Silver Spring
Name
Employee
151
Name
Twitter
Name
Next Earnings Date
2024-05-09
Name
Latest SEC Filings
Name
ELUT's Discussions on Twitter

Elutia Inc Stock (ELUT) Financials Data

Elutia Inc (ELUT) Revenue 2024

ELUT reported a revenue (TTM) of $35.35 million for the quarter ending December 31, 2023, a -3.34% decline year-over-year.
loading

Elutia Inc (ELUT) Net Income 2024

ELUT net income (TTM) was -$37.66 million for the quarter ending December 31, 2023, a -14.47% decrease year-over-year.
loading

Elutia Inc (ELUT) Cash Flow 2024

ELUT recorded a free cash flow (TTM) of -$22.11 million for the quarter ending December 31, 2023, a -0.61% decrease year-over-year.
loading

Elutia Inc (ELUT) Earnings per Share 2024

ELUT earnings per share (TTM) was -$2.06 for the quarter ending December 31, 2023, a +14.17% growth year-over-year.
loading
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative products to address the device protection, women's health, orthobiologics, cardiovascular, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
medical_devices STE
$207.82
price up icon 0.77%
$287.87
price up icon 0.46%
medical_devices PHG
$26.82
price up icon 0.98%
medical_devices ZBH
$121.66
price up icon 2.70%
$128.37
price up icon 1.36%
medical_devices EW
$85.25
price up icon 0.22%
Cap:     |  Volume (24h):